SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5th Annual Neuro Perspectives Conference, being held virtually on Thursday, June 27, 2024.
A webcast of the presentation will be available on the “Events & Presentations” page at 7:00 a.m. ET within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
This email address is being protected from spambots. You need JavaScript enabled to view it.
1AB (media)
Dan Budwick
973-271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.
Argot Partners (investors)
Laura Perry
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.88 |
| Daily Change: | -0.10 -5.05 |
| Daily Volume: | 576,625 |
| Market Cap: | US$184.110M |
November 25, 2024 September 19, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
